- Platform: meet
- Source: Read.ai 01J8T9YP0EE172DDGJCJRJ0389 (via Ben Ornstein’s account, imported 2026-08-06)
Transcript
Ben Ornstein: But yeah, so basically how this goes is I’m going to ask some softball questions, things you have 100% answered before. This is prerecorded, so if there’s anything that you’d like to lie, like while we’re recording, saying, hey, actually, I didn’t like how I framed this, or afterwards, when I turn this into a document, you’re going to have the ability to edit it and say whatever you’d like, So you will have a chance. RadLogics Inc: I would appreciate it if you can send me your transcript. Probably most of the errors would be because of the automatic transcribing, transcription, but nevertheless, I’d like to review it and then send you a, um, send you a final version. Ben Ornstein: Yeah, no, of course. So yeah, how it goes is I take the transcript, I turn it into the case study and then I’ll send you that draft. RadLogics Inc: Yep. Cool. All right. Ben Ornstein: Okay. Well, yeah. Um, and how do you pronounce your first name? Is it motion? RadLogics Inc: You’ve got it. Perfect, okay. Originally from Israel, so it cannot be mistaken, right? Pretty much. Ben Ornstein: That’s right. I’m Jewish as well, so that works out. RadLogics Inc: Oh, good for you. So Moshe. Ben Ornstein: Moshe. That’s how I think I knew it. Okay, great. Okay, so Moshe, please introduce yourself and your startup. RadLogics Inc: If you’re talking about my most recent one, Red Lodge, would be happy to do that. I’m a tech entrepreneur, but Logix is actually my fifth startup I’ve been involved with, three of which I’ve actually started myself, co-founded, and overall, those five, sold four of them, and pulled the plug on one of them. Because we didn’t get close enough to hitting the big opportunity that we were anticipating originally. Ben Ornstein: Gotcha. I have four for five. You’re pretty good. RadLogics Inc: Yeah. So in summary, yeah, 25 plus goes to of tech entrepreneurship. My background is in EE and then MBA with Peter Drucker at the Claremont in California. And throughout the years, I’ve increasingly became more well-versed in the world of early stage tech entrepreneurship. This is really my middle name, maybe my first name actually. Ben Ornstein: That’s awesome. RadLogics Inc: That’s what I do. Ben Ornstein: Very cool, very cool. What can you share about the fundraising journey? I guess for RadLogix, I saw you raised a decent chunk of money. Yeah, could you say like how many funding rounds were raised and if you’re comfortable, the valuations, et cetera. RadLogics Inc: Not gonna disclose valuations. Ben Ornstein: Totally fine. RadLogics Inc: But yeah, so RedLogix in particular, it went, it helped rather. And this is actually one of my first experience actually in digital health, in health related stuff per se. Never done health or medicine, medical-related stuff before that. And I was warned at the get-go from colleagues and whatnot that with healthcare, you need patients. And true to be told, that’s indeed the case. So we’re talking about longer-term turnaround time in terms of even from proof of concept to actually clinical validation, to regulatory approval, you know, and a whole lot. So how does that relate to your question? We found that the best investors that would be attuned to what we were trying to do from the early stage would not be VCs in particular, but rather home offices or group of angel clubs or whatnot, which we found typically to be more patient, understand the necessary steps that go between initial funding to actually have a viable product that you could sell. So this has been our approach, and we were quite successful in that. Wanted money, it’s all relative some of other of the other players in this domain. You know they raise literally hundreds of millions of dollars in some cases which I think is actually a bad thing to them because the industry is still nascent and There’s just no way you can make the returns that you know VCS in particular you know expect so we call I hit the home offices, angel clubs, for a total investment so far of about $13 million, $13 million total, which is actually very modest to what we’ve achieved with it. Ben Ornstein: Yeah, 100%. RadLogics Inc: We pioneered the domain of using AI in medical imaging analysis. We were the first company to get FDA approval in this space. We were the first one to launch commercially in this space, the first one to launch on AWS or any cloud for that matter in this space. Many, many firsts. We were voted by the industry, by the user industry, user if you will, the best new vendor back in the day when we just launched the solution commercially after it was FDA approved. Yeah. Ben Ornstein: That’s amazing. Very cool. RadLogics Inc: Thank you. Ben Ornstein: And that 13 million, how many rounds was that over? RadLogics Inc: Oh, this was, uh, essentially in, in, um, well, I preceded the company with my own investment. Yep. And then we had two rounds. We had, we had, uh, a seed, uh, angels from the Valley and then, uh, serious say within extension. Cool. Awesome. That’s what, that’s what, that’s the stage we’re at because, uh, again, the business needs to be developed before we could warrant a bigger round for essentially scale-up. We’re not there yet. Not because of us, because of the industry. It’s just slow to adopt. Ben Ornstein: Yeah, that’s so unfortunate, right? Because it’s like your tech might be there, but… RadLogics Inc: Yeah, the major adoption is still ahead for us and for the rest of Yeah. Ben Ornstein: And so when you raised this funding, what did you plan ahead of time for the cash to be allocated for? Were there milestones you wanted to hit? RadLogics Inc: Yes. When I first invested Pre-Seed, the idea was to build a proof of concept, a software just to show that this could actually do the trick. One trick, you start narrow and we focus on that and it did. Which is where we raised our seed round. The purpose of the seed round was to reach FDA approval, pretty much. Obviously other things, you know, improve the product, get some more clinical validation from a couple of other major academic medical centers. But, By and large, it was to get FDA and then, well, this was brewing to have a plan for essentially go to market. This is what we did. So we had a few early adopter customers, and then we raised the series A to expand and go beyond that. Awesome. All right, cool. Ben Ornstein: So you said you preceded the round, the precede round. For the seed, how did you decide which investors would be a good fit? RadLogics Inc: So per my comment before that, we knew what to look for specifically. And we essentially looked for funding sources, again, more like boutique kind of institutions, if you will. And groups of people that have keen interest in healthcare and improving healthcare with technology. And we found that there are actually quite a bit of these that are available. And what I found most striking is that most of these grew up out of a personal story for the either, you know, the leading MD, okay, or otherwise. Or it became someone that was very influential on the MD, the managing director of the fund. With personal stories about struggling either personally, let’s say with cancer, it can be diagnosed with imaging, or having a family member go through that. We found many, quite a few of these focused on these kinds of new technologies to improve things for people, for patients, come from that kind of a background. So it was very, actually very touching to talk to these people and understand that they’re not just investing it for the ROI or the multiple investment capital, but rather because it serves a much, much, much deeper purpose for them. Ben Ornstein: That’s amazing to have investors that are there for the mission. They want to see the solution come to fruition. RadLogics Inc: Yeah, if it takes a year or two, they don’t care. They want to see something that really brings some new facility or a big improvement compared to how things are done today. Ben Ornstein: Yeah. I mean, what a great alignment with your investors. That’s amazing. RadLogics Inc: looking for, I specifically spent quite a bit of time finding or essentially shortlisting the groups that I thought would be most appropriate. UNKNOWN_SPEAKER: Yeah. Ben Ornstein: And you just talked about you find them. How did you get in touch with these investors? RadLogics Inc: Through connections, through my network, through others. Long story, very different routes. To how you get in touch with people, with some of the doctors that we actually worked with in our beta sites, or proof of concept, yeah, clinical trial sites, which actually said, oh, I might have someone that would be interested in what you guys are doing. Once they saw it worked at their facility, they said, oh, this is cool. Let me connect you with these guys. They might be interested. Kind of that, a lot of that. Ben Ornstein: That’s awesome. Was there any cold outreach done? Say again? Was there any cold outreach done? Cold outreach? RadLogics Inc: Not much. I don’t believe in that. I have, you know, I’ve been in this, done that, you know, for quite a few years. I got my network of, you know, people that I trust and know. And, and, and again, the buildup of the, uh, the particular interactions with the, uh, with the people at the hospitals or the clinics that we’ve worked with initially, provided an additional, if you will, stream of potential investors. Ben Ornstein: Yeah, no, that makes a lot of sense. RadLogics Inc: I don’t think there was any cold turkey call, like cold call to any particular, hey, you know, this is me, this is us, this is what we do. Would you like to hear more about it? No, almost zero. Maybe I’m forgetting someone, but no. That’s not my approach. Ben Ornstein: Yeah, especially when you already have the connections, right? RadLogics Inc: Like you have a necessary connection to get- I found it, and this is kind of like part of the methodology that I’ve built over the years for myself, is to really engage, you know, potential. Customers or potential customers once you show them the value of what you’re doing they would open up and Find it, you know beneficial also to them specifically to to provide Connections that might be interested in investment. Ben Ornstein: Yep And when you were pitching these, you know the angels the family offices, etc. What did you emphasize in the pitch? RadLogics Inc: Oh the critical emphasis was the value that we bring to patients. This is the baseline. And again, once this is kind of like sorted out and people understand almost instinctively, you can take it to the next level of, you know, the typical, you know, financial speak or, okay, you know, investors speak of differentiation, go to market, the sales strategy, marketing strategy, and channel development, all that. But first, this is what I found, which is kind of like different than what I had in previous lives, is that people want to see, or at least those kind of people that I’ve contacted, they want to see the undisputable, excuse me, undisputable benefit to the patients before anything else. Ben Ornstein: Yeah. I mean, it makes sense, right? For the product you’re selling, right? RadLogics Inc: Yes and no. Some, some, I don’t want to say cynically, but a lot of companies or, you know, products are meant to, you know, just, just make money. And maybe sometimes there’s, there’s actually a trade-off between patient, I would say the quality of patient care, whatever you want to call it, and the economic benefit. And this goes beyond, you know, the kind of investors that I was looking for or talk to. This goes back to my intrinsic value. The first thing I did when I made a decision to look for an opportunity in the healthcare space is that it will not be a trade-off between patient’s outcome and financial return for the institution that provide the care. I would otherwise not do that. And this is one of the beauty, most beautiful things about the RedLogix solution or approach. It is an incredible combination of do-gooders, okay, at all levels. Everybody wins, the patient first and foremost, but also the provider, hospital or clinic, and also the insurance, the health insurance is actually benefiting, because we introduce better quality, better efficiency, reduce costs, you know misdiagnosis sometimes so everybody wins everybody wins there’s no trade-off there’s no win-lose there’s no like um zero-sum game situation here at all anywhere you look it’s all uh gaining essentially at enterprise for all stakeholders involved and you have a better business I love those businesses. You cannot have, which is why I stuck to it and put my own money into it. I mean, this is like a finding. It’s like a diamond mine that I found, that we found in the early days. And it was just unresistable once I realized we can actually do something that checks all the boxes. Ben Ornstein: That’s incredible. Yeah. I can see why you’re so passionate about it. If everyone can win, I mean, just that’s so exciting. RadLogics Inc: So we’re good to ourselves and as I said to the patients but also the business and for the health care provider is not is not injured it actually benefits economically from if they implement what we got. Ben Ornstein: For sure. Did you apply any urgency tactics to drive investors to close out a round? RadLogics Inc: Sense of urgency. Well, there’s always that because we really wanted to, for instance, once we finished the proof of concept in our first clinical trial in Santa Clara, California. Okay, so the sense of urgency, but again, it’s not the sense of urgency that was driven by you know, a competitive situation where the market is just watching to come up with something. So there was no rush whatsoever. The rush, if you will, it was more of like an internal rush. The sooner we get this FDA approved, the sooner we can actually provide it to, you know, real people, real patients, real doctors. So it was an internal rush, more than anything else. Yeah, no, that makes a lot There was no competition per se, at least not initially. Later on, other companies pretty much, you know, got into this domain as well. I don’t want to say copycat it, although there’s some of that, of course, but it says actually, you know, it’s actually a good, I actually like that because it means that they actually hit on something, right? Ben Ornstein: Right, it means you’ve created something valuable, right? RadLogics Inc: Yeah, so once that happened, yeah, maybe there’s a little bit more to just streamline how we do, you know, the regulatory approval cycle, say, okay? Sure. Oh, yeah, absolutely. So, we put some effort into that. So, like, our next FDA approval turnaround time was much quicker. But it’s not just thanks to us. It’s also thanks to the fact that we actually worked with FDA while we were doing our first one to pretty much educate educate them to what was coming and they got it. It took, you know, it’s FDA, it takes, it’s slow to learn. But it took, you know, about a year and they got the message. And now it’s a pretty standard regulatory, I would say set of rules that everybody adheres to. Ben Ornstein: That’s great. And in hindsight, of course, you make it sound so easy, but you know, what were the biggest challenges? RadLogics Inc: easy at all. It was very hard to convince investors to, I’m talking about the serious one, serious A, to jump the gun. Literally, this is what they had to do. A lot of, you know, belief in the vision and because there were no good comparables in the market. No good comparables. This is pioneering work also from the business perspective the business model how do you how do you integrate it into the existing workflows of you know within the providers you know data systems not trivial we have to invent all that and then working with AWS okay Verner you know CTO of Amazon AWS he said you’re gonna do what it is heavy German accent when I first Yeah, this is serious stuff. Yeah, this is what we’re going to do. And we’re going to run, we want to build, we told him we want to build a platform on your, on your platform that could analyze 1 million CT scans per day. He didn’t believe we could do it. We did. Ben Ornstein: That’s wild. RadLogics Inc: We actually tested it at that level of busy use. We never got to it commercially, but it was tested for it. So all those challenges had to be overcome. Ben Ornstein: Wow. That 1 million scans a day. RadLogics Inc: That’s crazy that you were able to process that, you know, with all the good stuff, you know, GPUs, AI, deep learning, all that fancy stuff, which we’re, we were probably among the first to actually use. We actually gave a presentation and we were invited to GTC, um, to, um, I’m not actually. The NVIDIA annual. Ben Ornstein: Oh, yes, yes, yes. RadLogics Inc: They actually invited us to present. And once we actually published our first results at scale, using, of course, their hardware, their tools, we presented our initial results years ago when this is all very, very nascent. Ben Ornstein: Are there any other, you know, unique or interesting interesting stories related to fundraising that you’d like to bring up? RadLogics Inc: Fundraising? No, for me, obviously, somebody needs to run the show and focus on this. But for me, fundraising is a necessary, I don’t want to say evil, but it’s a necessary task to be a CEO, founder. But I prefer to most of my time looking for exceptional talent and talking to customers or potential customers. So again, this is why I use this network of colleagues, acquaintances or whatnot to try and streamline the process, if you will. So I only talk to people that were kind of like pre-sorted by people that I trust and So at least the introduction and all the preparatory work and early stage is done very quickly. And you know who are the best type of investors, at least in my mind, based on my experience? The best type of investors are the ones that are going to tell you no quickly. Yeah. Yeah. 100%. Ben Ornstein: Don’t waste your time. RadLogics Inc: You don’t want to waste your time. So I appreciate this. Kind of like get my way into these kinds of people. Ben Ornstein: I mean, I’m all about transparency, right? I love talking to the people who don’t bullshit, who just tell it how it is. RadLogics Inc: And if they are sincere about not saying no, because they’re still considering it, maybe they want to talk to some colleagues, maybe they want to talk to some contacts in the industry or in some hospitals, that’s all nice and dandy. But if it’s stretched too long, that eventually it’s going to hurt the company. Ben Ornstein: And you may not even want those types of people on your cap table. RadLogics Inc: You’re absolutely right. Ben Ornstein: Yeah, makes sense. Now, what’s one piece of fundraising advice that you’d give other founders? RadLogics Inc: One piece of fundraising advice, I would say, do a really deep Um, homework assignment to, uh, find is relating to related to what I’ve said before, to try and find the, uh, the type of investors that are culturally, uh, out of aligned with your type of business and what you’re trying to achieve. Um, in terms of, you know, use of proceeds for, for the, for the round that you’re raising. For. These would be my two best advices. Ben Ornstein: No, that’s amazing. I agree, right? That’s super important. RadLogics Inc: This is based on my experience. This is not some textbook. This is how I’ve lived my life. Ben Ornstein: Yeah, I like it. Who is an investor that you would recommend other founders work with? RadLogics Inc: What do you mean by that? Ben Ornstein: investor that you’ve previously worked with, people could potentially take capital from, from your experience, who would you recommend as an investor? RadLogics Inc: I just said it as a general sense of how you shortlist the list of potential investors that you want to address. I’m not going to specify specific ones on this call. Ben Ornstein: Okay. Totally fine. Yep. All good. RadLogics Inc: Are there any resources that you would recommend to founders this could be you know books podcasts newsletters anything Podcast newsletters, you know, they’re the usual Suspects I like to sometimes read as a guy named Thomas Tungus you’re familiar with him. I am NOT He’s a VC. And I like his tack on things, his perspective. And so this will be like one off-the-cuff recommendation for something to read and keep abreast on. And obviously, the guys at A16Z, sometimes they have some good thoughts communicated to the community. And Dreesen and Horowitz, of a banner, yeah. And Mark, they might actually provide some wisdom that would help other entrepreneurs. Ben Ornstein: Oh, they’re great, right? They put out a lot of good stuff. That’s right. RadLogics Inc: And even though I disagree with them politically, the fundamental notion of what entrepreneurship, tech entrepreneurship is all about, I’m pretty much on the same page with them. Ben Ornstein: Absolutely. And last question here would be, you know, would you have any uptakes regarding the fundraising process? RadLogics Inc: Um, what, what, what do you have in mind? Ben Ornstein: Things that you believe that some people may disagree with you about regarding fundraising and investing specifically. RadLogics Inc: Oh, disagree with me. Um, Yes, maybe. The most unimportant, I would say, item to focus on, some people would say only initially, don’t focus on it. But throughout the fundraising process is valuation. Don’t bring it up early. And this might be a little bit of a paradox for common wisdom, common thoughts. I don’t think that has to be a central, I mean, unless it’s ridiculous, of course, right? I wouldn’t spend too much time on that at all. And in fact, as far as early stage or even seed and sometimes even beyond that, Depending on you know, the size of the business opportunity the market and so what it’s on I would recommend Delaying okay Every any sense that has to do with valuation to later stages as much as possible only like free commercialization Then you should talk, you know actual valuation with with equity stakes other than that. I recommend founders follow I Okay. Essentially, a debt, convertible debt instruments throughout funding as much as possible before they really need, you know, the big bucks to scale. Then you need valuation because otherwise, you know, equity markets tend to be a little bit dislocated. If you don’t get the But early stage, don’t bother with valuation and try to convince the investor not to insist on that. If you could. It gives you a lot of leeway later on. And it’s not like investors are, you know, losing, but obviously, you know, there’s a discount cap model. I’m pretty familiar with that. So I’ve been there, done that, you know, many, many times. Highly recommend those instruments until it’s absolutely necessary to do an equity round in the early stages. Obviously not serious B, C, D, E, whatever, obviously. I’m talking about when the company is still nascent and through the stages that we’ve been through, in particular with Redlogix, that’s what I recommend. Ben Ornstein: That’s great. No, that’s an awesome way end here. And you’ve talked about, you didn’t get a chance to talk about your other previous businesses. I’d love to include that in the beginning section here. Do you want to briefly talk about those? RadLogics Inc: Yeah, I’ve been involved in four other startups before RodLogix. First one, I just moved to California from Tel Aviv, from Israel. Was I was like employee number seven. Probably the last time I was actually an employee anyway. When I got hired as an employee, right? And yeah, so I kind of like let the project, the product and the go-to-market eventually ended up being the main reason this company was acquired by HP. Ben Ornstein: Oh, wow. RadLogics Inc: Back in the day. The next one was a company called Kinematrix. It’s based in Pasadena. That first company was in Anaheim. Next company was Kinematrix based in Pasadena. It was in a totally different domain, but the same idea of creating value out of big data. It’s geophysical data. Make long story short, my team that I brought in transformed this company from a manufacturer of a device or a small subsystem in a device that they’ve been doing for, I don’t know, 10, 15 before that, to a solution company with a big software component and analysis, a decision support system of oil, if you will. And we sold it to OYO, which is an UK 300 Japanese company. The third one was a company that I started as a CEO, founder, in the mobile space, the nascent mobile space at the time. And we created a software platform to help seller carriers optimize the use of their spectrum. Highly valuable, you know, licensed spectrum. Among other things, and this is like a almost like a first, we pioneered this through the use of location data of where the actual users are located in real time to optimize how the system works and also provide eventually we also who are among the first to provide the so-called value-added services to the end users based on this data that we’ve managed for the carriers. Ben Ornstein: Very cool. Wow, that’s interesting. RadLogics Inc: This one got sold to a subsidiary of Schlumberger. They actually created a group within Schlumberger to deal and take opportunities that came through in the mobile space. And then they’ve actually spin it off as a company called Exalto. And this is the company that actually acquired us. They eventually, later on, merged with their biggest competitor to become Gemalta of today. Oh, wow. And then my fourth company, before Logix, it was a company I started with two colleagues, one a tech guru in a domain of, again, wireless communication, a company called Stellaris. And we created a solution to optimize the use of spectrum, but non-licensed spectrum, unlike Celadon, where they use, you know, licensed spectrum, which the carriers pay lots of money for. Wi-Fi is another place where there’s essentially the same kind of a problem, even more so because it’s unlicensed, meaning it’s free. Everyone can use the spectrum. And it’s very limited because it’s free, so the government is not totally stupid. They don’t want to look Too much spectrum for free. Okay, so it’s free Wi-Fi is a free spectrum and In the beginning it was who cared, you know, you just use it in Wi-Fi. It’s great, right? But as as it became more and more successful and prevalent they can an issue of congestion Became apparent and this is kind of like what we solved reason we was that our solution, which was tested and verified in multiple, I would say, settings, pilots, if you will, we couldn’t get it through the sanitization committee, the IEEE 802.11 committee. We were pretty much, the main pushback was from Intel. And there are a lot of rumors of why that was. My best explanation was that Intel was actually working on something similar, and they wanted to introduce their technology into the standard, into the next update to the standard, and they just wouldn’t have any of what we were, you know, suggesting, even though technically, performance-wise, it was superior. Yeah. So I decided to pull the plug on it. I mean, there was an opportunity to continue with this and, you know, find some verticals that actually can use a non-standard, if you will, solution, but I opted to look for something new. And talking about lessons to founders, never forget the element of an opportunity cost. Never forget it. It’s critical for one’s life in general, and particularly for a founder’s life. Opportunity costs. If you do something, you’re not doing something else that might actually be better. More worthy of your time and money. And energy and blah, blah, blah. Ben Ornstein: You only get so many swings at bat, right? RadLogics Inc: Absolutely. So, and then I took a break for about six months and then I came across the opportunity in, in, uh, digital health. And this is how red logics came to be. Ben Ornstein: Wow. What a journey you’ve had. That’s crazy. RadLogics Inc: Thank you. I’m, I’m not a dull moment, right? Ben Ornstein: No. I mean, that’s why I started my career in banking. And I was like, this is the most boring. RadLogics Inc: What kind of banking, if I may ask? Ben Ornstein: Yeah. So I was an analyst, just a financial analyst in the derivatives funding aspect of Morgan Stanley. It was pretty boring. I was on Excel all day long doing the same report every day. I was like, this is a joke. What am I doing here? I’m non-technical, but I knew I wanted to be in startups because while I was working at Morgan Stanley, I started a podcast and I started a, um, a clothing brand with a few friends of mine. Neither of those were successful by any means, but what it did for me is I learned. I love building things and I wanted to be a part of something from the very beginnings. And so that, that was my foray into startups and I’m, I’m never leaving. RadLogics Inc: You got it. I cannot blame you. I got the same bug. Ben Ornstein: Yeah, right. I believe it. RadLogics Inc: It’s uncurable. Ben Ornstein: It’s uncurable, exactly. RadLogics Inc: I think only death cures it. Ben Ornstein: Pretty much, right? RadLogics Inc: Yeah, absolutely. Ben Ornstein: All right. Moshe, I really appreciate the time. I really enjoyed chatting. RadLogics Inc: I hope this was helpful and valuable. I have no idea what you guys want to do with this, but please send me the Transcript or you know, the edited your edited version. I’ll just take a quick look and I’ll I’ll send you a Quick feedback. Ben Ornstein: Yeah. No, absolutely Yeah, so what we’re gonna end up doing this maybe I didn’t say that in the beginning This is a part of a library of like 60 plus Interviews and their payment gated behind, you know a pay a paywall and so Yeah, this will be a part of that case study for founders and prospective founders who are who are paying for it to be able to get a lot of value from, and I think this will be a great one. RadLogics Inc: Thank you. I appreciate the opportunity to participate. Ben Ornstein: Yeah, no, and I appreciate you taking the time. Yeah, I don’t know how long it’s going to take for me to get this to you. I’d say a week at the very most. RadLogics Inc: No rush. I’m in no rush. I just want to make sure that I get a chance to review it before you do it. Ben Ornstein: Oh yeah, no. We’ll never publish it before you get to see it. RadLogics Inc: Terrific. UNKNOWN_SPEAKER: Awesome. Ben Ornstein: Moshe, you have a great rest of your day. RadLogics Inc: Great weekend. Have a good weekend. Bye for now. You as well. Great to meet you. Bye.